Treatment-Emergent Psychosis With Aripiprazole

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Aripiprazole, the latest atypical antipsychotic to receiveapproval by the U.S. Food and Drug Administration, is uniquein its action as a partial agonist at dopamine receptors.¹ Partialagonists can function as net agonists or net antagonists, dependingon the amount of naturally occurring full agonist neurotransmitterthat is present. Aripiprazole has antagonist activityat dopamine-2 (D2) receptors in a hyperdopaminergic environmentand agonist activity in a hypodopaminergic environment.’ ‹